These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan. Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369 [TBL] [Abstract][Full Text] [Related]
32. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Yamamoto R; Nakayama M; Hasegawa T; Miwako N; Yamamoto H; Yokoyami K; Ikeda M; Kato N; Hayakawa H; Takahashi H; Otsuka Y; Kawaguchi Y; Hosoya T Adv Perit Dial; 2002; 18():131-4. PubMed ID: 12402604 [TBL] [Abstract][Full Text] [Related]
33. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Fusshoeller A Pediatr Nephrol; 2008 Jan; 23(1):19-25. PubMed ID: 17638023 [TBL] [Abstract][Full Text] [Related]
34. [Encapsulating peritoneal sclerosis]. Ryckelynck JP; Béchade C; Bouvier N; Ficheux M; Hurault de Ligny B; Lobbedez T Nephrol Ther; 2017 Jun; 13(4):211-219. PubMed ID: 28576435 [TBL] [Abstract][Full Text] [Related]
35. Absence of gadolinium deposits in the peritoneal membrane of patients with encapsulating peritoneal sclerosis. Goffin E; Schroeder JA; Weingart C; Decleire PY; Cosyns JP Nephrol Dial Transplant; 2010 Apr; 25(4):1334-9. PubMed ID: 20007759 [TBL] [Abstract][Full Text] [Related]
36. Vasculopathy plays an important role during the development and relapse of encapsulating peritoneal sclerosis with conventional peritoneal dialysis solutions. Tawada M; Ito Y; Banshodani M; Yamashita M; Shintaku S; Sun T; Suzuki Y; Kinashi H; Kubo Y; Ando M; Yamaguchi M; Katsuno T; Mizuno M; Kawanishi H Nephrol Dial Transplant; 2021 Jul; 36(8):1519-1526. PubMed ID: 32437531 [TBL] [Abstract][Full Text] [Related]
37. Encapsulating peritoneal sclerosis in an Italian center: thirty year experience. Vizzardi V; Sandrini M; Zecchini S; Ravera S; Manili L; Cancarini G J Nephrol; 2016 Apr; 29(2):259-267. PubMed ID: 26521254 [TBL] [Abstract][Full Text] [Related]
38. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Habib AM; Preston E; Davenport A Nephrol Dial Transplant; 2010 May; 25(5):1633-8. PubMed ID: 20037174 [TBL] [Abstract][Full Text] [Related]
39. Liver cirrhosis with encapsulating peritoneal sclerosis after 4 years of peritoneal dialysis: A case report. Watanabe-Kusunoki K; Kusunoki Y; Goto J; Kukita K Medicine (Baltimore); 2021 Dec; 100(51):e28350. PubMed ID: 34941145 [TBL] [Abstract][Full Text] [Related]
40. Risk factors for encapsulating peritoneal sclerosis: Analysis of a 36-year experience in a University Hospital. Nakao M; Yamamoto I; Maruyama Y; Morishita M; Nakashima A; Matsuo N; Tanno Y; Ohkido I; Ikeda M; Yamamoto H; Yokoyama K; Yokoo T Nephrology (Carlton); 2017 Nov; 22(11):907-912. PubMed ID: 27556577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]